Drug Type Small molecule drug |
Synonyms AOB87172, MLN-7243, TAK 243 |
Target |
Action inhibitors |
Mechanism UBA1 inhibitors(Ubiquitin-like modifier-activating enzyme 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H20F3N5O5S2 |
InChIKeyKJDAGXLMHXUAGV-DGWLBADLSA-N |
CAS Registry1450833-55-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 1 | United States | 24 Mar 2025 | |
Advanced Lymphoma | Phase 1 | United States | 24 Mar 2025 | |
Indolent Non-Hodgkin Lymphoma | Phase 1 | United States | 24 Mar 2025 | |
Metastatic Solid Tumor | Phase 1 | United States | 24 Mar 2025 | |
Refractory Malignant Solid Neoplasm | Phase 1 | United States | 24 Mar 2025 | |
Relapsed Solid Neoplasm | Phase 1 | United States | 24 Mar 2025 | |
Anemia, Refractory, With Excess of Blasts | Phase 1 | United States | 12 Mar 2025 | |
Recurrent Acute Leukemia | Phase 1 | United States | 12 Mar 2025 | |
Recurrent Myelodysplastic Syndrome | Phase 1 | United States | 12 Mar 2025 | |
Refractory acute myeloid leukemia | Phase 1 | United States | 12 Mar 2025 |
Not Applicable | - | wbrrnywgbf(nxqavursgo) = vamfgewnwc dygwbdksnh (sydmbvexnf ) | - | 01 Nov 2021 | |||
Radiotherapy | wbrrnywgbf(nxqavursgo) = rnevqkpyzi dygwbdksnh (sydmbvexnf ) | ||||||
Not Applicable | - | hpdzvqbkrl(cyhduavooq) = ikvzlkjsxa zkvgwwvamw (ykxpanrfyv ) View more | - | 01 Nov 2020 | |||
Phase 1 | 29 | (Schedule A: TAK-243 1 mg) | jcjdobdpwt = dmldbzezif wwuseavpan (fumcmgfamc, iawtdamtkv - gckbpcsczg) View more | - | 14 Mar 2019 | ||
(Schedule A: TAK-243 2 mg) | jcjdobdpwt = vwdpvgvwor wwuseavpan (fumcmgfamc, ujtsiwjjgo - usgrfwtoyn) View more |